Drug Profile
Research programme: T cell-based therapeutics - Opus Bio/University of Pennsylvania
Alternative Names: CAR T-cell based therapies; CAR+ T; Chimeric antigen receptor T cell therapies; LG 690Latest Information Update: 05 Jan 2022
Price :
$50
*
At a glance
- Originator Lentigen Corporation; University of Pennsylvania
- Developer Medical University of South Carolina; Opus Bio; University of Pennsylvania
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Leukaemia; Lymphoma; Malignant melanoma
Most Recent Events
- 22 Mar 2018 Discontinued - Preclinical development for Malignant melanoma, Lymphoma and Leukaemia in USA (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Leukaemia in USA (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lymphoma in USA (IV, Infusion)